Press Releases from Idillo Inc (1 total)
Study Shows Dupixent Users Face 4.5X Higher Cancer Risk
JAMA Dermatology Study Shows 4.5-Fold Increased Risk of Cutaneous T-Cell Lymphoma in Patients Using Dupixent for Eczema Treatment.
Orlando, FL - November 16, 2025 - Idillo…
Go To Page:
